Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

OBJECTIVE: To compare the efficacy and safety of two doses of once-weekly dulaglutide, a glucagon-like peptide 1 receptor agonist, to sitagliptin in uncontrolled, metformin-treated patients with type 2 diabetes. The primary objective was to compare (for noninferiority and then superiority) dulagluti...

Descripción completa

Detalles Bibliográficos
Autores principales: Nauck, Michael, Weinstock, Ruth S., Umpierrez, Guillermo E., Guerci, Bruno, Skrivanek, Zachary, Milicevic, Zvonko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2014
Materias:
Clinical Care/Education/Nutrition/Psychosocial Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113177/
https://www.ncbi.nlm.nih.gov/pubmed/24742660
http://dx.doi.org/10.2337/dc13-2761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113177/
https://www.ncbi.nlm.nih.gov/pubmed/24742660
http://dx.doi.org/10.2337/dc13-2761

Ejemplares similares